Trial Profile

Research Into the Effect of SGLT2 Inhibition on Left Ventricular Remodeling in Patients With Heart Failure and Diabetes Mellitus

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary)
Indications Chronic heart failure; Heart failure; Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms REFORM; The REFORM Trial

Most Recent Events

02 Sep 2024 Results assessing whether dapagliflozin reduced Epicardial adipose tissue in patients with type 2 diabetes and HF with reduced ejection fraction (HFrEF) were presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology.
03 Apr 2020 Results published in the Diabetes Care
26 Jul 2018 New source identified and integrated. (European Clinical Trials Database; EudraCT2014-002742-42)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com